Loading...

Pfizer Inc.

PFE.DEXETRA
Healthcare
Drug Manufacturers - General
20.72
0.00(0.00%)

Pfizer Inc. PFE.DE Peers

See (PFE.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
PFE.DE€20.72+0.00%121.3B17.78€1.20+7.53%
LLY.DE€661.30+0.00%633.2B63.45€10.53+0.72%
JNJ.DE€129.26+0.00%320.8B17.34€7.69+3.51%
4AB.DE€157.80+0.00%286.2B79.80€2.03+3.72%
ZEG.DE€118.65+0.00%188.4B28.19€4.31+2.25%
6MK.DE€67.10+0.00%175.5B11.65€6.00+4.25%
AMG.DE€237.85+0.00%127.7B24.90€9.54+3.56%
PFE.F€20.72+0.00%121B17.60€1.21+7.55%
GIS.DE€94.15+0.00%117.3B22.79€4.14+3.11%
SNW.DE€82.22+0.00%101.2B16.65€4.99+4.72%
Showing 1 to 10 of 15 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

PFE.DE vs LLY.DE Comparison

PFE.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PFE.DE stands at 121.3B. In comparison, LLY.DE has a market cap of 633.2B. Regarding current trading prices, PFE.DE is priced at €20.72, while LLY.DE trades at €661.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PFE.DE currently has a P/E ratio of 17.78, whereas LLY.DE's P/E ratio is 63.45. In terms of profitability, PFE.DE's ROE is +0.09%, compared to LLY.DE's ROE of +0.77%. Regarding short-term risk, PFE.DE is less volatile compared to LLY.DE. This indicates potentially lower risk in terms of short-term price fluctuations for PFE.DE.

Stock Price Comparison

Loading...

Frequently Asked Questions

;